No Detail Found!

Prognostic Importance of Metastatic Site in Intermediate-risk Group Metastatic Renal Cell Cancer Treated with Tyrosine Kinase Inhibitors

Author(s)
Cengiz Karacin Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital,Ankara,Turkey
Irem Bilgetekin Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital,Ankara,Turkey
Fatma Bugdayci Basal Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital,Ankara,Turkey
Omur Berna Oksuzoglu Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital,Ankara,Turkey
Abstract
Objective: To determine the prognostic importance of the metastatic site in metastatic renal cell cancer (mRCC) patients in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate-risk. Study design: Observational study. Place and Duration of Study: Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey, from January 2010 to November 2018. Methodology: Records of 113 mRCC patients, determined to be in the intermediate-risk group according to IMDC criteria, were reviewed retrospectively. All patients used a tyrosine kinase inhibitor sunitinib or pazopanib for metastatic disease. Patients records included age, gender, metastatic site, number of metastases and treatment regimen. The Kaplan-Meier method was used for survival analysis, and a Cox regression model was formed. Results: The median age of the patients was 58 years (Q1 - Q3: 44 - 66 years) and 87.6% of the patients had e2 metastatic sites. The most common metastatic sites were the lung (51.3%), lymph nodes (26.5%), bone (26.5%) and brain (17.7%). Median overall survival (OS) was shorter in the patients with bone and brain metastasis than in those without (15.0 monthsvs. 21.0 months, p = .026 and 14.0 months vs. 21.0 months, p = .009, respectively). Multivariate analysis showed that brain and bone metastasis were independent prognostic risk factors (HR: 2.43, p = .017 and HR: 2.10, p = .042, respectively). Conclusion: Bone and brain metastasis had a negative e ect on OS in IMDC intermediate-risk group mRCC patients.
Publication Details
Page(s) 590-594
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 30, Issue: 6, Year: 2020

Request the full text from PASTIC

Keywords
Prognosis, Renal cell carcinoma, Brain metastasis, Metastatic site, Bone metastasis
0

Citations

0

Downloads

51

Views